Search Results
Your search for Matthew Stenger,Matthew Stenger matches 7217 pages
Showing 201 - 250Mantle Cell Lymphoma: Predictive Value of Measurable Residual Disease With Rituximab Maintenance
In an analysis from the European Mantle Cell Lymphoma Elderly Trial reported in the Journal of Clinical Oncology, Hoster et al found that outcomes with rituximab maintenance were better in patients aged ≥ 60 years with mantle cell lymphoma who had measurable residual disease (MRD)-negative vs...
Erdafitinib vs Chemotherapy in Previously Treated, FGFR-Mutated Advanced Urothelial Carcinoma
As reported in The New England Journal of Medicine by Yohann Loriot, MD, PhD, and colleagues, cohort 1 of the phase III THOR trial has shown improved overall survival with erdafitinib vs chemotherapy in patients with locally advanced, unresectable, or metastatic urothelial carcinoma with...
Adding Durvalumab to Chemoradiotherapy in Locally Advanced Cervical Cancer
As reported in The Lancet Oncology by Bradley J. Monk, MD, and colleagues, the phase III CALLA trial showed no significant improvement in progression-free survival with the addition of durvalumab to chemoradiotherapy in previously untreated patients with locally advanced cervical cancer. Study...
First-Line Treatment of Advanced HCC: Addition of Pembrolizumab to Lenvatinib
As reported in The Lancet Oncology by Josep M. Llovet, MD, and colleagues, the phase III LEAP-002 trial has shown that the addition of pembrolizumab to lenvatinib in the first-line treatment of unresectable hepatocellular carcinoma did not reach statistical superiority thresholds for overall or...
Everolimus for Pediatric Recurrent/Progressive Low-Grade Glioma
In the phase II PNOC001 trial reported in the Journal of Clinical Oncology, Daphne A. Haas-Kogan, MD, MBA, and colleagues found that everolimus showed activity in pediatric patients with recurrent or progressive low-grade glioma. PI3K/AKT/mTOR pathway activation was not correlated with clinical...
Disitamab Vedotin in Previously Treated Patients With Advanced HER2-Positive Urothelial Carcinoma
In a combined analysis of two Chinese phase II trials (RC48-C005 and RC48-C009) reported in the Journal of Clinical Oncology, Sheng et al found that the antibody-drug conjugate disitamab vedotin—an anti-HER2 antibody conjugated with monomethyl auristatin—produced promising results in patients with...
Adding Tiragolumab to Atezolizumab and Chemotherapy in Previously Untreated Extensive-Stage SCLC
As reported in the Journal of Clinical Oncology by Charles M. Rudin, MD, PhD, and colleagues, the phase III SKYSCRAPER-02 trial showed no progression-free or overall survival benefit with the addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor tiragolumab to atezolizumab and...
Predicting Primary Ovarian Insufficiency in Childhood Cancer Survivors
As reported in The Lancet Oncology, Im et al have developed risk-prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer. Study Details In the study, models to predict age-specific risk of primary ovarian insufficiency were evaluated among 5-year survivors...
Colorectal Cancer: Incidence and Time to Recurrence
In a nationwide Danish cohort study reported in JAMA Oncology, Nors et al found the 5-year risk of recurrence after surgery for stage I to III colorectal cancer decreased over time and the time to recurrence was shorter with a more advanced disease stage. Study Details The study used the Danish...
Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...
Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors
In a European study reported in the Journal of Clinical Oncology, Heymer et al found that the risk of subsequent colorectal cancer was elevated among childhood cancer survivors who had undergone abdominopelvic radiotherapy. Study Details The study used data from the PanCareSurFup Study—a...
Inotuzumab Ozogamicin–Based Induction in Older Patients With Philadelphia Chromosome–Negative B-Cell–Precursor ALL
In a German phase II trial (INITIAL-1) reported in the Journal of Clinical Oncology, Matthias Stelljes, MD, and colleagues found that inotuzumab ozogamicin–based induction therapy followed by age-adapted chemotherapy was associated with promising outcomes in newly diagnosed patients older than age...
Trastuzumab Plus Gemcitabine/Cisplatin in Advanced HER2-Positive Biliary Tract Adenocarcinoma
In an Indian phase II trial reported in the Journal of Clinical Oncology, Ostwal et al found that trastuzumab plus gemcitabine/cisplatin was active in treatment-naive patients with advanced HER2-positive biliary tract adenocarcinoma. Study Details In the investigator-initiated multicenter trial, 90 ...
Incidence of Breast Cancer After False-Positive Mammography
In a Swedish study reported in JAMA Oncology, Mao et al found that women with a false-positive mammography result were more likely to be subsequently diagnosed with breast cancer compared to women with no false-positive result. Study Details The study involved data from 45,213 women who received a...
Adding Atezolizumab to Perioperative Chemotherapy in Resectable Esophagogastric Cancer
As reported in the Journal of Clinical Oncology by Lorenzen et al, the phase II portion of the German-Swiss phase II/III DANTE/IKF-s633 trial showed promising results with the addition of atezolizumab to perioperative chemotherapy in patients with resectable esophagogastric cancer. Study Details In ...
Novel Uterine Cancer Detection Method for Women With Abnormal Uterine Bleeding
In a UK single-institution study (EPI-SURE) reported in The Lancet Oncology, Evans et al found that the novel WID-qEC DNA methylation test outperformed ultrasonography in detecting uterine cancer in women with abnormal uterine bleeding. Study Details The prospective observational study invited...
Outcomes With Olaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer in the PROfound Trial
In an analysis of the phase III PROfound trial reported in the Journal of Clinical Oncology, Joaquin Mateo, MD, PhD, and colleagues found that olaparib improved outcomes vs abiraterone or enzalutamide among the subgroup of patients with metastatic castration-resistant prostate cancer who had...
Bosutinib in Pediatric Chronic Myeloid Leukemia
On September 26, 2023, bosutinib (Bosulif) was approved for pediatric patients aged 1 year and older with chronic-phase Philadelphia chromosome–positive chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy.1 New capsule dosage form strengths of 50 mg...
First-Line Dabrafenib Plus Trametinib vs Standard Chemotherapy for Pediatric Low-Grade Glioma With BRAF V600 Mutations
As reported in The New England Journal of Medicine by Eric Bouffet, MD, of the Hospital for Sick Children, Toronto, and colleagues, a phase II trial has shown a significant improvement in objective response rate and other efficacy outcomes with first-line dabrafenib plus trametinib vs standard...
Metastatic Castration-Resistant Prostate Cancer: Efficacy of Anti-PSMA Antibody With Alpha Emitter
In a phase I study reported in the Journal of Clinical Oncology, Scott T. Tagawa, MD, MS, FASCO, FACP, and colleagues determined the recommended phase II dose and described preliminary activity of actinium-225–J591—an anti–prostate-specific membrane antigen (PSMA) monoclonal antibody (J591)...
Early-Stage Cervical Cancer: Defining Follow-up After Fertility-Sparing Surgery
In a Dutch retrospective cohort study reported in The Lancet Oncology, Schuurman et al identified follow-up strategies based on cytology and human papillomavirus (HPV) testing after fertility-sparing surgery for early-stage cervical cancer. Study Details The nationwide population-based study used...
Axillary Soft-Tissue Involvement in Lymph Node–Positive Breast Cancer
In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Naoum et al found that pathologic exploration of axillary soft tissue in patients with lymph node–positive breast cancer is a critical element in predicting disease outcome and in determining axillary...
Blinatumomab as an Alternative to First-Line Intensive Chemotherapy in Pediatric B-Cell ALL
In a retrospective study reported in the Journal of Clinical Oncology, Hodder et al found that blinatumomab was effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons with B-cell acute lymphoblastic leukemia (ALL) who were...
Adding Pembrolizumab to Chemotherapy for Previously Untreated Advanced Pleural Mesothelioma
As reported in The Lancet by Chu et al, a phase III trial conducted in Canada, Italy, and France showed that the addition of pembrolizumab to chemotherapy improved survival in previously untreated patients with advanced pleural mesothelioma. Study Details In the multicenter open-label trial, 440...
PROpel Trial: Olaparib Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer Unselected for HRR Mutation Status
As reported in The Lancet Oncology by Fred Saad, MD, of the Centre Hospitalier de l’Université de Montréal, and colleagues, the final prespecified overall survival analysis of the phase III PROpel trial has shown no significant benefit with the addition of first-line olaparib to abiraterone in...
Early Breast Cancer: Effect of Radiotherapy to Regional Nodes
As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of...
Overall Survival With CTC Count–Driven Treatment in Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the French phase III STIC CTC trial showed a nonsignificant overall survival benefit with a circulating tumor cell (CTC) count–driven approach to therapy vs physician’s choice in the first-line...
Addition of Adjuvant HIPEC to Standard Chemotherapy in Locally Advanced Colon Cancer
As reported in the Journal of Clinical Oncology by Zwanenburg et al, 5-year findings from the Dutch COLOPEC trial indicated that the addition of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) to systemic chemotherapy did not improve overall survival vs chemotherapy alone in patients...
Modified vs Standard Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma
In a UK phase II trial (PRISM) reported in the Journal of Clinical Oncology, Vasudev and colleagues found that ipilimumab given every 12 weeks vs every 3 weeks in combination with nivolumab resulted in a significantly reduced rate of treatment-related grade ≥ 3 adverse events in treatment-naive...
Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia: GLOW Trial 4-Year Follow-up
As reported in The Lancet Oncology by Niemann et al, the 4-year follow-up of the phase III GLOW trial has shown a continued progression-free survival benefit with fixed-duration ibrutinib/venetoclax vs chlorambucil/obinutuzumab in the first-line treatment of chronic lymphocytic leukemia in patients ...
Racial Disparities in Guideline-Concordant Care in Early-Onset Colorectal Cancer in the United States
In a study reported in the Journal of Clinical Oncology, Nogueira et al found that among U.S. Black and White patients with early-onset colorectal cancer, Black patients were more likely to receive poorer and less timely care. As stated by the investigators: “Young individuals racialized as Black...
Ofranergene Obadenovec With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer
In a phase III trial (OVAL Study/GOG 3018) reported in the Journal of Clinical Oncology, Arend et al found that the addition of ofranergene obadenovec to paclitaxel did not improve survival outcomes in patients with platinum-resistant ovarian cancer. Ofranergene obadenovec is a gene-based targeted...
AI-Based Pathology for Assessing Sensitivity to Atezolizumab/Bevacizumab in HCC
As reported in The Lancet Oncology, Zeng et al developed an artificial intelligence (AI)-based pathology method that distinguished between better and poorer response to treatment with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC). As stated by the investigators:...
Long-Term Organ Preservation With Total Neoadjuvant Therapy in Rectal Adenocarcinoma
In a 5-year follow-up of the phase II OPRA trial reported in the Journal of Clinical Oncology, Verheij et al found that many patients receiving total neoadjuvant therapy for rectal adenocarcinoma remained free of the need for total mesorectal excision. Study Details In the U.S. multicenter trial,...
Osimertinib With or Without Chemotherapy in EGFR-Mutant Advanced NSCLC
As reported in The New England Journal of Medicine by Planchard et al, the phase III FLAURA2 trial has shown superior progression-free survival with osimertinib plus platinum-based chemotherapy vs osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Effect of Bendamustine Prior to Apheresis on Outcomes in Large B-Cell Lymphoma Treated With CAR T-Cell Therapy
In a retrospective study reported in the Journal of Clinical Oncology, Iacoboni et al found that preapheresis bendamustine exposure was associated with poorer outcomes among patients with relapsed or refractory large B-cell lymphoma receiving CD19-targeted chimeric antigen receptor (CAR) T-cell...
Addition of Tumor Treating Fields Therapy to Standard Systemic Therapy Improves Survival in Metastatic NSCLC after Progression on Platinum-Based Therapy
In a phase III trial (LUNAR) reported in The Lancet Oncology, Ticiana Leal, MD, Winship Cancer Institute at Emory University, and colleagues found that the addition of Tumor Treating Fields (TTFields) therapy to standard systemic therapy improved overall survival in patients with metastatic...
Subsequent Cancer Diagnosis After No Diagnosis With Urgent Suspected Cancer Referral
In a national cohort study in England reported in The Lancet Oncology, Scott et al found a high rate of subsequent cancer diagnosis in persons with an urgent suspected cancer referral that did not result in cancer diagnosis. As noted by the investigators, “Following referral for investigation of...
Metastatic Castration-Resistant Prostate Cancer: Single-Dose LuPSMA Plus Maintenance Pembrolizumab
In a single-institution phase I dose-expansion trial reported in The Lancet Oncology, Aggarwal et al found that a single dose of lutetium-177–PSMA-617 (LuPSMA) followed by pembrolizumab maintenance was associated with activity in patients with metastatic castration-resistant prostate cancer. Study...
Adding Pembrolizumab to Trastuzumab and Chemotherapy in HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: KEYNOTE-811
In interim analyses from the phase III KEYNOTE-811 trial reported in The Lancet, Yelena Y. Janjigian, MD, and colleagues found that the addition of pembrolizumab to trastuzumab and chemotherapy in first-line treatment of patients with locally advanced or metastatic HER2-positive...
Adjuvant Atezolizumab/Bevacizumab vs Active Surveillance in Resected or Ablated High-Risk Hepatocellular Carcinoma
As reported in The Lancet by Shukui Qin, MD, and colleagues, interim analysis of the phase III IMbrave050 trial has shown significantly better recurrence-free survival with adjuvant atezolizumab/bevacizumab vs active surveillance in patients who underwent curative-intent resection or ablation for...
Adding HIPEC to Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases
As reported in the Journal of Clinical Oncology by Rau et al, the German phase III GASTRIPEC-I trial showed no improvement in overall survival with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery in patients with gastric cancer and synchronous peritoneal...
Addition of First-Line Pembrolizumab to Chemotherapy, With or Without Bevacizumab, in Advanced Cervical Cancer: Final Overall Survival Results From KEYNOTE-826
In an analysis reported in the Journal of Clinical Oncology, Bradley J. Monk, MD, FACS, FACOG, and colleagues described final overall survival results from the phase III KEYNOTE-826 trial, which evaluated the addition of first-line pembrolizumab to chemotherapy, with or without bevacizumab, in...
First-Line Selpercatinib vs Chemotherapy With or Without Pembrolizumab in RET Fusion–Positive NSCLC
An interim analysis of the phase III LIBRETTO-431 trial has shown significantly improved progression-free survival with first-line selpercatinib vs platinum-based chemotherapy with or without pembrolizumab in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The...
Bispecific T-Cell Engager Tarlatamab in Previously Treated Patients With Small Cell Lung Cancer
In the phase II DeLLphi-301 trial—presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA92) and reported by Ahn et al in The New England Journal of Medicine—tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3, exhibited activity in...
Perioperative Durvalumab in Resectable NSCLC: AEGEAN Trial
As reported in The New England Journal of Medicine by John V. Heymach, MD, PhD, and colleagues, the phase III AEGEAN trial has shown that perioperative durvalumab improved event-free survival and pathologic complete response (pCR) rate in patients with resectable non–small cell lung cancer ...
Addition of First-Line Pembrolizumab to Chemotherapy in HER2-Negative Advanced Gastric Cancer
As reported in The Lancet Oncology by Sun Young Rha, MD, and colleagues, the phase III KEYNOTE-859 trial has shown that the addition of first-line pembrolizumab to chemotherapy was associated with a statistically significant improvement in overall survival in patients with HER2-negative advanced...
Advanced RET-Mutant Medullary Thyroid Cancer: First-Line Selpercatinib
As presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA3) and reported in The New England Journal of Medicine by Hadoux et al, an interim analysis from the phase III LIBRETTO-531 trial has shown improved progression-free survival with selpercatinib vs...
3-Year Overall Survival With Tebentafusp in Previously Untreated Advanced Uveal Melanoma
In an analysis presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA50) and reported in The New England Journal of Medicine by Jessica C. Hassel, MD, and colleagues, overall survival at 3 years in the phase III IMCgp100-202 trial continued to favor...
Addition of Amivantamab to Chemotherapy in First-Line Treatment of Advanced NSCLC With EGFR Exon 20 Insertions
The phase III PAPILLON study has shown that the addition of amivantamab-vmjw to chemotherapy significantly improved progression-free survival in the first-line treatment of advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The findings were presented at the European Society...
